Medtronic plc (MDT) FCF Payout Ratio: 67.09%
Is Medtronic plc’s FCF payout ratio high or low?
Medtronic plc's FCF payout ratio of 67.09% is in line with its 5-year average of 67.70%, around the middle of its 5-year range (56.59%–78.95%).
The FCF payout ratio for Medtronic plc (MDT) is 67.09%. It is below its 12-month average by 1.54% (68.14%).
MDT FCF Payout Ratio Chart
MDT Average FCF Payout Ratio Chart
MDT Current vs Average FCF Payout Ratio Chart
MDT FCF Payout Ratio Metrics
FCF PAYOUT RATIO
67.09%
FCF PAYOUT RATIO AVG TTM
68.14%
FCF PAYOUT RATIO AVG 3Y
71.43%
FCF PAYOUT RATIO AVG 5Y
67.70%
FCF PAYOUT RATIO AVG 10Y
60.24%
FCF PAYOUT RATIO AVG 15Y
49.91%
FCF PAYOUT RATIO AVG 20Y
44.79%
CURRENT VS TTM AVG
-1.54%
CURRENT VS 3Y AVG
-6.08%
CURRENT VS 5Y AVG
-0.90%
CURRENT VS 10Y AVG
+11.38%
CURRENT VS 15Y AVG
+34.42%
CURRENT VS 20Y AVG
+49.77%
Payout Ratio Comparison
FCF Payout Ratio
67.1%
Earnings Payout Ratio
75.7%
Dividend Yield
3.54%
FCF Yield
5.25%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2026 | $5.43B | $3.64B | 67.1% |
| 2025 | $5.18B | $3.59B | 69.2% |
| 2024 | $5.20B | $3.67B | 70.5% |
| 2023 | $4.58B | $3.62B | 79.0% |
| 2022 | $5.98B | $3.38B | 56.6% |
| 2021 | $4.88B | $3.12B | 63.9% |
| 2020 | $6.02B | $2.89B | 48.1% |
| 2019 | $5.87B | $2.69B | 45.9% |
| 2018 | $3.62B | $2.49B | 69.0% |
| 2017 | $5.63B | $2.38B | 42.2% |
| 2016 | $4.17B | $2.14B | 51.3% |
| 2015 | $4.33B | $1.34B | 30.9% |
| 2014 | $4.56B | $1.12B | 24.5% |
| 2013 | $4.43B | $1.05B | 23.8% |
| 2012 | $3.85B | $1.02B | 26.5% |
| 2011 | $3.19B | $969.00M | 30.3% |
| 2010 | $3.50B | $907.00M | 25.9% |
| 2009 | $3.21B | $843.00M | 26.2% |
| 2008 | $2.88B | $565.00M | 19.6% |
| 2007 | $2.29B | $504.00M | 22.1% |
| 2006 | $963.20M | $464.80M | 48.3% |
| 2005 | $2.37B | $404.90M | 17.1% |
| 2004 | $2.42B | $351.50M | 14.5% |
| 2003 | $1.70B | $304.20M | 17.9% |
| 2002 | $1.20B | $278.80M | 23.2% |
| 2001 | $1.39B | $240.70M | 17.3% |
| 2000 | $699.90M | $189.50M | 27.1% |
| 1999 | ($788.50M) | $131.90M | N/A (Loss) |
| 1998 | $441.90M | $102.90M | 23.3% |
| 1997 | $273.40M | $90.70M | 33.2% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Medtronic plc FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc FCF Payout Ratio FAQ
- What is the FCF payout ratio for Medtronic plc (MDT)?
- The FCF payout ratio for MDT stock is 67.09%.
- Is Medtronic plc's FCF payout ratio high or low?
- Medtronic plc's FCF payout ratio of 67.09% is in line with its 5-year average of 67.70%, around the middle of its 5-year range (56.59%–78.95%).
- What is the TTM average FCF payout ratio for Medtronic plc (MDT)?
- The TTM average FCF payout ratio for MDT stock is 68.14%.
- What is the 3Y average FCF payout ratio for Medtronic plc (MDT)?
- The 3Y average FCF payout ratio for MDT stock is 71.43%.
- What is the 5Y average FCF payout ratio for Medtronic plc (MDT)?
- The 5Y average FCF payout ratio for MDT stock is 67.70%.
- What is the 10Y average FCF payout ratio for Medtronic plc (MDT)?
- The 10Y average FCF payout ratio for MDT stock is 60.24%.
- What is the 15Y average FCF payout ratio for Medtronic plc (MDT)?
- The 15Y average FCF payout ratio for MDT stock is 49.91%.
- What is the 20Y average FCF payout ratio for Medtronic plc (MDT)?
- The 20Y average FCF payout ratio for MDT stock is 44.79%.
Medtronic plc FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2026-04-24 | 67.07% |
| 2025-04-30 | 69.22% |
| 2024-04-30 | 70.50% |
| 2023-04-30 | 78.95% |
| 2022-04-30 | 56.59% |
| 2021-04-30 | 63.87% |
| 2020-04-30 | 48.07% |
| 2019-04-30 | 45.85% |
| 2018-04-30 | 68.97% |
| 2017-04-30 | 42.23% |
| 2016-04-30 | 51.27% |
| 2015-04-30 | 30.87% |
| 2014-04-30 | 24.46% |
| 2013-04-30 | 23.84% |
| 2012-04-30 | 26.50% |
| 2011-04-30 | 30.35% |
| 2010-04-30 | 25.94% |
| 2009-04-30 | 26.22% |
| 2008-04-30 | 19.60% |
| 2007-04-30 | 22.06% |
| 2006-04-30 | 48.26% |
| 2005-04-30 | 17.10% |
| 2004-04-30 | 14.52% |
| 2003-04-30 | 17.92% |
| 2002-04-30 | 23.16% |
| 2001-04-30 | 17.29% |
| 2000-04-30 | 27.08% |
| 1998-04-30 | 23.29% |
| 1997-04-30 | 33.17% |
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha